Karo Bio Selects Reaxys and Reaxys Medicinal Chemistry to Support Chemists in Research and Development

AMSTERDAM, July 9, 2013 /PRNewswire/ --

Comprehensive and relevant chemistry and bioactivity related content reduces research timescales and supports rapid user adoption

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Karo Bio, a developer of innovative drugs for large medical needs, has started to use Reaxys® and Reaxys® Medicinal Chemistry. Karo Bio has chosen the solutions to support its chemists in their research and development objectives, ensuring they have quick and easy access to state of the art chemistry information.

"Comprehensive content is critical to our chemists and the Reaxys solutions give them more relevant results in a single search than other solutions could offer," said Maria Sjöberg, Chief Scientific Officer at Karo Bio. "Not only do our chemists have access to more data, including biological as well as chemical information, but the content is more applicable to their research. We expect the availability of the Reaxys Medicinal Chemistry information alone will reduce research and development time by approximately 20 percent."

Reaxys, with its recent expansion of chemistry data and capabilities now encompassing content of over 16,000 periodicals, is recognized by users as having the deepest and richest fact-base of experimentally measured chemistry data. Reaxys Medicinal Chemistry offers access to data from a vast repository of peer-reviewed journal articles and patents and is interoperable with Reaxys. Adding this content to Karo Bio's information sources means that chemists will have readily available access to relevant information. That, coupled with the flexibility of the search function and the way results are presented, will enable chemists to more quickly identify and prioritize viable compounds, helping reduce the time it takes to bring innovative drugs to market.

"Researchers in life sciences face an ever growing challenge in making confident and successful decisions in a changing landscape," said Dr. Juergen Swienty-Busch, Head of Product Management for Reaxys. "Karo Bio has a unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals. We are excited that the Reaxys solutions will play a part in increasing the speed at which these projects to discover innovative compounds come to fruition."

Reaxys and Reaxys Medicinal Chemistry are part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA and Embase.

For further information go to http://www.elsevier.com/reaxys.

About Karo Bio

Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas neuropsychiatry, inflammation, autoimmune diseases and cancer. An important foundation for the company's activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 43 employees and is listed on NASDAQ OMX Stockholm. http://www.karobio.com

About Reaxys®

Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit Reaxys.

Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact
Liz Griffioen
Elsevier
+31-20-485-2247
L.Griffioen@elsevier.com

SOURCE Elsevier




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.